Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

2.

Author's Reply to Proost: "Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients".

Jelliffe RW.

Clin Pharmacokinet. 2017 Mar;56(3):313-316. doi: 10.1007/s40262-016-0482-4. No abstract available.

PMID:
28035590
3.

Comment on "Management of Atrial Fibrillation in Critically Ill Patients".

Jelliffe R.

Crit Care Res Pract. 2016;2016:8985161. doi: 10.1155/2016/8985161. Epub 2016 Aug 24. No abstract available.

4.

Author's reply to Veloso HH Comment on "The Role of Digitalis Pharmacokinetics in Converting Atrial Fibrillation and Flutter to Sinus Rhythm".

Jelliffe RW.

Clin Pharmacokinet. 2016 May;55(5):637-9. doi: 10.1007/s40262-016-0381-8. No abstract available.

PMID:
27000759
6.

Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.

Lalande L, Bourguignon L, Bihari S, Maire P, Neely M, Jelliffe R, Goutelle S.

Antimicrob Agents Chemother. 2015 Sep;59(9):5181-9. doi: 10.1128/AAC.00462-15. Epub 2015 Jun 15.

7.

Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance.

Jelliffe RW, Schumitzky A, Bayard D, Fu X, Neely M.

Ther Drug Monit. 2015 Jun;37(3):389-94. doi: 10.1097/FTD.0000000000000168.

8.

Optimal methodology is important for optimal pharmacokinetic studies, therapeutic drug monitoring and patient care.

Jelliffe R.

Clin Pharmacokinet. 2015 Sep;54(9):887-92. doi: 10.1007/s40262-015-0280-4. No abstract available.

PMID:
25948018
9.

Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients.

Glatard A, Bourguignon L, Jelliffe RW, Maire P, Neely MN, Goutelle S.

Antimicrob Agents Chemother. 2015;59(6):2986-94. doi: 10.1128/AAC.04132-14. Epub 2015 Mar 9.

10.

Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

Louie A, Liu W, VanGuilder M, Neely MN, Schumitzky A, Jelliffe R, Fikes S, Kurhanewicz S, Robbins N, Brown D, Baluya D, Drusano GL.

J Infect Dis. 2015 Apr 15;211(8):1326-33. doi: 10.1093/infdis/jiu603. Epub 2014 Oct 31.

11.

The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy.

Goutelle S, Bourguignon L, Maire P, Jelliffe RW, Neely MN.

Curr Pharm Des. 2014;20(39):6191-206. Review.

PMID:
25190098
12.

Concerning antiplatelet therapy.

Jelliffe R.

Am J Cardiol. 2014 Jun 15;113(12):2086-7. doi: 10.1016/j.amjcard.2014.03.028. Epub 2014 Mar 27. No abstract available.

PMID:
24878132
13.

The role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to regular sinus rhythm.

Jelliffe RW.

Clin Pharmacokinet. 2014 May;53(5):397-407. doi: 10.1007/s40262-014-0141-6.

14.

A two-compartment population pharmacokinetic-pharmacodynamic model of digoxin in adults, with implications for dosage.

Jelliffe RW, Milman M, Schumitzky A, Bayard D, Van Guilder M.

Ther Drug Monit. 2014 Jun;36(3):387-93. doi: 10.1097/FTD.0000000000000023.

15.

Are vancomycin trough concentrations adequate for optimal dosing?

Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP.

Antimicrob Agents Chemother. 2014;58(1):309-16. doi: 10.1128/AAC.01653-13. Epub 2013 Oct 28.

16.

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.

Åsberg A, Midtvedt K, van Guilder M, Størset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, Neely MN.

Transpl Int. 2013 Dec;26(12):1198-207. doi: 10.1111/tri.12194. Epub 2013 Oct 15.

17.

Amikacin population pharmacokinetics in critically ill Kuwaiti patients.

Matar KM, Al-lanqawi Y, Abdul-Malek K, Jelliffe R.

Biomed Res Int. 2013;2013:202818. doi: 10.1155/2013/202818. Epub 2013 Jan 30.

18.

Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.

Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary R, Chubatiuk A, Schumitzky A.

J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):189-99. doi: 10.1007/s10928-013-9302-8. Epub 2013 Feb 13.

19.

Software for dosage individualization of voriconazole for immunocompromised patients.

Hope WW, Vanguilder M, Donnelly JP, Blijlevens NM, Brüggemann RJ, Jelliffe RW, Neely MN.

Antimicrob Agents Chemother. 2013 Apr;57(4):1888-94. doi: 10.1128/AAC.02025-12. Epub 2013 Feb 4.

20.

Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw.

Sedghizadeh PP, Jones AC, LaVallee C, Jelliffe RW, Le AD, Lee P, Kiss A, Neely M.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Feb;115(2):224-32. doi: 10.1016/j.oooo.2012.08.455. Epub 2012 Dec 12.

21.

Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis.

Schaudinn C, Gorur A, Webster P, Jones AC, Neely M, Jelliffe RW, Le AD, Sedghizadeh PP.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Oct;114(4):480-6. doi: 10.1016/j.oooo.2012.06.006.

PMID:
22986243
22.
23.

Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW.

Ther Drug Monit. 2012 Aug;34(4):467-76. doi: 10.1097/FTD.0b013e31825c4ba6.

24.

Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients.

Charhon N, Neely MN, Bourguignon L, Maire P, Jelliffe RW, Goutelle S.

Antimicrob Agents Chemother. 2012 Apr;56(4):1862-9. doi: 10.1128/AAC.05634-11. Epub 2012 Jan 30.

25.

Nonparametric population modeling and Bayesian analysis.

Jelliffe R, Neely M, Schumitzky A, Bayard D, Van Guilder M, Botnen A, Bustad A, Laing D, Yamada W, Bartroff J, Tatarinova T.

Pharmacol Res. 2011 Oct;64(4):426. doi: 10.1016/j.phrs.2011.04.008. Epub 2011 Apr 23. No abstract available.

PMID:
21699981
26.

Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin.

Goutelle S, Bourguignon L, Jelliffe RW, Conte JE Jr, Maire P.

J Theor Biol. 2011 Aug 7;282(1):80-92. doi: 10.1016/j.jtbi.2011.05.013. Epub 2011 May 18.

PMID:
21605569
27.

Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.

Bondareva IB, Jelliffe RW, Andreeva OV, Bondareva KI.

J Clin Pharm Ther. 2011 Oct;36(5):625-36. doi: 10.1111/j.1365-2710.2010.01215.x. Epub 2010 Nov 10.

28.

Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.

Neely M, Decosterd L, Fayet A, Lee JS, Margol A, Kanani M, di Iulio J, von Schoen-Angerer T, Jelliffe R, Calmy A.

Antimicrob Agents Chemother. 2010 Nov;54(11):4619-25. doi: 10.1128/AAC.00712-10. Epub 2010 Sep 7.

29.

Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.

Walsh TJ, Goutelle S, Jelliffe RW, Golden JA, Little EA, DeVoe C, Mickiene D, Hayes M, Conte JE Jr.

Antimicrob Agents Chemother. 2010 Aug;54(8):3451-9. doi: 10.1128/AAC.01647-09. Epub 2010 May 3.

30.

Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician.

Neely M, Jelliffe R.

J Clin Pharmacol. 2010 Jul;50(7):842-7. doi: 10.1177/0091270009356572. Epub 2010 Feb 12. Review. No abstract available.

PMID:
20154293
31.

Voriconazole pharmacokinetics and pharmacodynamics in children.

Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J.

Clin Infect Dis. 2010 Jan 1;50(1):27-36. doi: 10.1086/648679.

32.

Visual estimation of patients' body weight in hospital: the more observers, the better?

Goutelle S, Bourguignon L, Bertrand-Passeron N, Jelliffe RW, Maire P.

Pharm World Sci. 2009 Aug;31(4):422-425. doi: 10.1007/s11096-009-9295-y. Epub 2009 Apr 22.

PMID:
19387861
33.

Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.

Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE Jr, Jelliffe RW.

Antimicrob Agents Chemother. 2009 Jul;53(7):2974-81. doi: 10.1128/AAC.01520-08. Epub 2009 Apr 20.

34.

Estimation of creatinine clearance.

Jelliffe R.

J Clin Pharmacol. 2008 Oct;48(10):1242-4; author reply 1244. doi: 10.1177/0091270008322910. No abstract available.

PMID:
18812612
35.
36.

A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine.

Kwa A, Sprung J, Guilder MV, Jelliffe RW.

Ther Drug Monit. 2008 Jun;30(3):379-89. doi: 10.1097/FTD.0b013e3181778fa3.

38.

Noninvasive hemodynamic monitoring for combat casualties.

Shoemaker WC, Wo CC, Lu K, Chien LC, Rhee P, Bayard D, Demetriades D, Jelliffe RW.

Mil Med. 2006 Sep;171(9):813-20.

PMID:
17036597
39.

Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.

Bondareva IB, Jelliffe RW, Gusev EI, Guekht AB, Melikyan EG, Belousov YB.

J Clin Pharm Ther. 2006 Jun;31(3):211-21.

PMID:
16789986
40.

Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Bustad A, Terziivanov D, Leary R, Port R, Schumitzky A, Jelliffe R.

Clin Pharmacokinet. 2006;45(4):365-83.

PMID:
16584284
41.

Outcome prediction by a mathematical model based on noninvasive hemodynamic monitoring.

Shoemaker WC, Wo CC, Lu K, Chien LC, Bayard DS, Belzberg H, Demetriades D, Jelliffe RW.

J Trauma. 2006 Jan;60(1):82-90.

PMID:
16456440
42.

A stochastic control program to predict outcome and to support therapeutic decisions: a preliminary report.

Shoemaker WC, Bayard DS, Wo CC, Botnen A, Ahmedpour N, Gandhi A, Demetriades D, Jelliffe RW.

J Clin Monit Comput. 2005 Jun;19(3):223-30.

PMID:
16244846
43.

Outcome prediction in chest injury by a mathematical search and display program.

Shoemaker WC, Bayard DS, Wo CC, Chan LS, Chien LC, Lu K, Jelliffe RW.

Chest. 2005 Oct;128(4):2739-48.

PMID:
16236950
44.

Mathematical program for outcome prediction and therapeutic support for trauma beginning within 1 hr of admission: a preliminary report.

Shoemaker WC, Bayard DS, Botnen A, Wo CC, Gandhi A, Chien LC, Lu K, Martin MJ, Chan LS, Demetriades D, Ahmadpour N, Jelliffe RW.

Crit Care Med. 2005 Jul;33(7):1499-506.

PMID:
16003054
45.

Stochastic model for outcome prediction in acute illness.

Shoemaker WC, Bayard DS, Wo CC, Botnen A, Chan LS, Chien LC, Lu K, Demetriades D, Belzberg H, Jelliffe RW.

Comput Biol Med. 2006 Jun;36(6):585-600. Epub 2005 Jun 24.

PMID:
15979603
46.

Pharmacokinetics of ethambutol in children and adults with tuberculosis.

Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, Ashkin D, Auclair B, Berning SE, Jelliffe RW, Jaresko GS, Peloquin CA.

Int J Tuberc Lung Dis. 2004 Nov;8(11):1360-7.

PMID:
15581206
47.

Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms.

Gan SH, Ismail R, Wan Adnan WA, Zulmi W, Jelliffe RW.

J Clin Pharm Ther. 2004 Oct;29(5):455-63.

PMID:
15482390
48.

A Bayesian approach to tracking patients having changing pharmacokinetic parameters.

Bayard DS, Jelliffe RW.

J Pharmacokinet Pharmacodyn. 2004 Feb;31(1):75-107.

PMID:
15346853
49.

Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.

Bondareva IB, Jelliffe RW, Sokolov AV, Tischenkova IF.

J Clin Pharm Ther. 2004 Apr;29(2):105-20.

PMID:
15068399
50.

Individual dose optimization: why and how.

Jelliffe R.

Int J Clin Pharmacol Ther. 2004 Mar;42(3):183-4. Review. No abstract available.

PMID:
15049439

Supplemental Content

Loading ...
Support Center